Home

Our Technology

Innovative Chemistry
Transformative Therapies

FDA “Fast Track” and “Breakthrough Therapy” designations received. 

About us

What We Do

We’re a biotech company committed to stemming the prescription drug abuse epidemic.

Investment

Long Term
Opportunity

Ensysce Biosciences Accelerates PF614-MPAR-102 Study

Ensysce Biosciences Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2 Read More
Ensysce Biosciences Advances Breakthrough Opioid With Built-In Overdose Protection Following Positive FDA Feedback Read More
Ensysce Biosciences Initiates Pivotal Phase 3 Study of PF614 Read More
Ensysce Biosciences Announces Speakers for Major Symposium at PAINWeek 2025 Read More
Ensysce Biosciences Awarded $5.3 Million in Continued NIDA Support to Advance Breakthrough Opioid Overdose Protection Read More

Our Team

Brilliant minds
and vision

We’re proud to say our team is made up of just that — people and minds both driven by passion and full of potential. Our company is led by a team of executives and directors with vast experience and proven track records in pain, drug development and commercialization.

D. Lynn Kirkpatrick, PhD

Chief Executive Officer

Dave Humphrey

Chief Financial Officer

Bill Schmidt, PhD

Chief Medical Officer.

Jeffrey Millard, PhD

Chief Operating Officer

Geoff Birkett

Chief Commercial Officer

Linda Pestano, PhD

Chief Development Officer